HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cheng-Chih Hsiao Selected Research

Bilateral Frontoparietal Polymicrogyria

1/2016Heparin interacts with the adhesion GPCR GPR56, reduces receptor shedding, and promotes cell adhesion and motility.
4/2011Disease-associated GPR56 mutations cause bilateral frontoparietal polymicrogyria via multiple mechanisms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Cheng-Chih Hsiao Research Topics

Disease

3Neoplasms (Cancer)
01/2016 - 11/2014
2Bilateral Frontoparietal Polymicrogyria
01/2016 - 04/2011
1Leukemia
01/2022
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022
1Infections
10/2021
1Bites and Stings (Sting)
01/2016
1Melanoma (Melanoma, Malignant)
01/2016
1Polymicrogyria
01/2016
1Starvation
08/2015
1Fibrosarcoma
11/2014

Drug/Important Bio-Agent (IBA)

4G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
01/2016 - 04/2011
2CytokinesIBA
10/2021 - 01/2016
2Proteins (Proteins, Gene)FDA Link
01/2016 - 01/2016
1venetoclaxIBA
01/2022
1Antiviral Agents (Antivirals)IBA
10/2021
1Transcription Factors (Transcription Factor)IBA
10/2021
1LigandsIBA
01/2016
1Poly I-CIBA
01/2016
1Protein Glutamine gamma Glutamyltransferase 2IBA
01/2016
1CollagenIBA
01/2016
1Annexin A5IBA
08/2015
1StaurosporineIBA
08/2015
1Cycloheximide (Cicloheximide)IBA
08/2015
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2015
1DNA (Deoxyribonucleic Acid)IBA
08/2015
1Matrix Metalloproteinase 14 (MT1-MMP)IBA
11/2014
1Tissue Inhibitor of Metalloproteinase-2IBA
11/2014
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
11/2014
1Matrix Metalloproteinases (MMPs)IBA
11/2014

Therapy/Procedure

1Therapeutics
01/2022